Restoring America

Conservative values, National renewal

The FDA’s new leadership must give rare disease patients a clearer path

Published



At her confirmation hearing, Dr. Heidi Overton, President Donald Trump’s nominee to lead the Food and Drug Administration, called rare-disease treatments a “key priority.” The agency is also shaping PDUFA VIII, a five-year agreement that will determine FDA funding and its approach to reviewing new drugs. This is a rare opportunity and a serious responsibility.

To make that priority a reality, Overton must strengthen FDA capacity and provide clear, efficient regulatory pathways that can help save lives.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.